These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. On the horizon: pathways for drug development in Alzheimer's disease. Hake AM; Farlow MR Clin Geriatr Med; 2004 Feb; 20(1):141-52. PubMed ID: 15062492 [No Abstract] [Full Text] [Related]
4. Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome. Prasher VP; Fung N; Adams C Int J Geriatr Psychiatry; 2005 May; 20(5):496-7. PubMed ID: 15852458 [No Abstract] [Full Text] [Related]
5. Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias. Masterman D Clin Geriatr Med; 2004 Feb; 20(1):59-68. PubMed ID: 15062487 [No Abstract] [Full Text] [Related]
6. [New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?]. Frölich L; Schmitt B; Calabrese P; Diener H; Förstl H; Gertz HJ; Hallauer JF; Hampel H; Ihl R; Rieke K; Riepe M; Supprian T Dtsch Med Wochenschr; 2005 Feb; 130(8):408-12. PubMed ID: 15717252 [No Abstract] [Full Text] [Related]
8. [Use of neuropsychological tests in the Cronos Project]. Bianchi G; Gasparini M; Caffari B; Sorrentino GC; Bianchi C; Bruno G; Maggini M; Raschetti R; Vanacore N Ann Ist Super Sanita; 2005; 41(1):69-74. PubMed ID: 16037653 [TBL] [Abstract][Full Text] [Related]
9. Common Alzheimer's drug flunks test of effectiveness. Initial improvements in cognitive ability made by cholinesterase inhibitors soon disappear. Health News; 2004 Oct; 10(10):11. PubMed ID: 15584119 [No Abstract] [Full Text] [Related]
10. [The characteristics of Alzheimer's Disease Units in relation to neuropsychological tests]. Sorrentino GC; Caffari B; Vanacore N; Maggini M; Raschetti R Ann Ist Super Sanita; 2005; 41(1):63-8. PubMed ID: 16037652 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacotherapy of a patient with Alzheimer's disease: interactions with the antidementive galantamine]. Schwalbe O; Wunderlich S; Kloft C Med Monatsschr Pharm; 2006 Jun; 29(6):222-4. PubMed ID: 16792199 [TBL] [Abstract][Full Text] [Related]
14. The treatment of Alzheimer's disease: the approach from a clinical specialist in the trenches. Hake AM Semin Neurol; 2002 Mar; 22(1):71-4. PubMed ID: 12170395 [TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical treatment of cognitive disorders in Alzheimer's disease. Senin U; Cherubini A; Palumbo B; Mecocci P Funct Neurol; 1997; 12(3-4):211-2. PubMed ID: 9218980 [No Abstract] [Full Text] [Related]
16. Advances in the treatment of Alzheimer's disease. Schneider LS Aging (Milano); 1998 Apr; 10(2):156-7. PubMed ID: 9666210 [No Abstract] [Full Text] [Related]
17. Galantamine improves gait performance in patients with Alzheimer's disease. Assal F; Allali G; Kressig RW; Herrmann FR; Beauchet O J Am Geriatr Soc; 2008 May; 56(5):946-7. PubMed ID: 18454755 [No Abstract] [Full Text] [Related]
18. Assessing the efficacy of cholinesterase inhibitor drugs. Hopper P; Trotter C Int J Geriatr Psychiatry; 2003 Jan; 18(1):86-7. PubMed ID: 12497561 [No Abstract] [Full Text] [Related]
19. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Harry RD; Zakzanis KK Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322 [TBL] [Abstract][Full Text] [Related]
20. [Cardiac effects of cholinesterase inhibitors: a reason for restraint?]. Salarbaks AM; Boomkamp-Snoeren CM; van Puijenbroek E; Jansen PA; van Marum RJ Tijdschr Gerontol Geriatr; 2009 Apr; 40(2):79-84. PubMed ID: 19472574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]